IBDEI2CX ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39960,1,3,0)
 ;;=3^Ocular Pain,Right Eye
 ;;^UTILITY(U,$J,358.3,39960,1,4,0)
 ;;=4^H57.11
 ;;^UTILITY(U,$J,358.3,39960,2)
 ;;=^5006382
 ;;^UTILITY(U,$J,358.3,39961,0)
 ;;=H57.12^^153^1932^15
 ;;^UTILITY(U,$J,358.3,39961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39961,1,3,0)
 ;;=3^Ocular Pain,Left Eye
 ;;^UTILITY(U,$J,358.3,39961,1,4,0)
 ;;=4^H57.12
 ;;^UTILITY(U,$J,358.3,39961,2)
 ;;=^5006383
 ;;^UTILITY(U,$J,358.3,39962,0)
 ;;=I10.^^153^1932^8
 ;;^UTILITY(U,$J,358.3,39962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39962,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,39962,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,39962,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,39963,0)
 ;;=L71.9^^153^1932^19
 ;;^UTILITY(U,$J,358.3,39963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39963,1,3,0)
 ;;=3^Rosacea,Unspec
 ;;^UTILITY(U,$J,358.3,39963,1,4,0)
 ;;=4^L71.9
 ;;^UTILITY(U,$J,358.3,39963,2)
 ;;=^5009276
 ;;^UTILITY(U,$J,358.3,39964,0)
 ;;=L71.8^^153^1932^18
 ;;^UTILITY(U,$J,358.3,39964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39964,1,3,0)
 ;;=3^Rosacea NEC
 ;;^UTILITY(U,$J,358.3,39964,1,4,0)
 ;;=4^L71.8
 ;;^UTILITY(U,$J,358.3,39964,2)
 ;;=^5009275
 ;;^UTILITY(U,$J,358.3,39965,0)
 ;;=L71.1^^153^1932^17
 ;;^UTILITY(U,$J,358.3,39965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39965,1,3,0)
 ;;=3^Rhinophyma
 ;;^UTILITY(U,$J,358.3,39965,1,4,0)
 ;;=4^L71.1
 ;;^UTILITY(U,$J,358.3,39965,2)
 ;;=^106083
 ;;^UTILITY(U,$J,358.3,39966,0)
 ;;=S05.31XA^^153^1932^13
 ;;^UTILITY(U,$J,358.3,39966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39966,1,3,0)
 ;;=3^Ocular Laceration Right Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,39966,1,4,0)
 ;;=4^S05.31XA
 ;;^UTILITY(U,$J,358.3,39966,2)
 ;;=^5020606
 ;;^UTILITY(U,$J,358.3,39967,0)
 ;;=S05.32XA^^153^1932^12
 ;;^UTILITY(U,$J,358.3,39967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39967,1,3,0)
 ;;=3^Ocular Laceration Left Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,39967,1,4,0)
 ;;=4^S05.32XA
 ;;^UTILITY(U,$J,358.3,39967,2)
 ;;=^5020609
 ;;^UTILITY(U,$J,358.3,39968,0)
 ;;=Z21.^^153^1932^2
 ;;^UTILITY(U,$J,358.3,39968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39968,1,3,0)
 ;;=3^Asymptomatic HIV Infection Status
 ;;^UTILITY(U,$J,358.3,39968,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,39968,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,39969,0)
 ;;=Z83.511^^153^1932^6
 ;;^UTILITY(U,$J,358.3,39969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39969,1,3,0)
 ;;=3^Family Hx of Glaucoma
 ;;^UTILITY(U,$J,358.3,39969,1,4,0)
 ;;=4^Z83.511
 ;;^UTILITY(U,$J,358.3,39969,2)
 ;;=^5063382
 ;;^UTILITY(U,$J,358.3,39970,0)
 ;;=Z83.518^^153^1932^5
 ;;^UTILITY(U,$J,358.3,39970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39970,1,3,0)
 ;;=3^Family Hx of Eye Disorder NEC
 ;;^UTILITY(U,$J,358.3,39970,1,4,0)
 ;;=4^Z83.518
 ;;^UTILITY(U,$J,358.3,39970,2)
 ;;=^5063383
 ;;^UTILITY(U,$J,358.3,39971,0)
 ;;=Z79.899^^153^1932^10
 ;;^UTILITY(U,$J,358.3,39971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39971,1,3,0)
 ;;=3^Long Term Current Drug Therapy NEC
 ;;^UTILITY(U,$J,358.3,39971,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,39971,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,39972,0)
 ;;=Z01.00^^153^1932^4
 ;;^UTILITY(U,$J,358.3,39972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39972,1,3,0)
 ;;=3^Eye/Vision Exam w/o Abnormal Findings
 ;;^UTILITY(U,$J,358.3,39972,1,4,0)
 ;;=4^Z01.00
 ;;^UTILITY(U,$J,358.3,39972,2)
 ;;=^5062612
 ;;^UTILITY(U,$J,358.3,39973,0)
 ;;=Z01.01^^153^1932^3
 ;;^UTILITY(U,$J,358.3,39973,1,0)
 ;;=^358.31IA^4^2
